{# ── Non-reliance notice. Reaching the live report with one of these means it did not meet the blocking bar (the 4.02 names this period outside the Item 4.02 body) or the viewer is staff. Either way the reader must not take the figures at face value. ── #}

Get notified when JNJ files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts
NYSE: JNJ JOHNSON & JOHNSON 8-K

J&J proposes $5.5B settlement to resolve 76,000 ovarian talc claims, requires 95% participation

Filed July 28, 2026 · Period ending July 27, 2026 · ~1 min read

Key Changes

  • high

    J&J commits $5.5B to settle remaining ovarian talc litigation covering ~76,000 claims, with first payment of up to $3B in 2027 and no further payments before 2028, contingent on 95% plaintiff participation.

    Exhibit 99.1 view on EDGAR →
  • high

    MDL court on July 22, 2026 ordered plaintiffs to justify why claims should not be dismissed for inability to prove specific causation, after plaintiffs withdrew experts in two bellwether cases following hearing that exposed methodological flaws.

    Exhibit 99.1 view on EDGAR →
  • medium

    Settlement would complete talc litigation resolution after J&J previously settled ~95% of mesothelioma lawsuits, all state consumer protection claims, and all talc-supplier disputes.

    Exhibit 99.1 view on EDGAR →

1 more material change behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.

Read 3 full reports/month free No card required. Takes 30 seconds.

Want to see a complete report first? Today's free report (IMMR 10-K) is open in full — no account needed.

Partner

Trade JNJ commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Was this report useful?

Source-verified from EDGAR · Narrative written by AI · Jul 29, 2026 · How we verify